Merrimack Pharmaceuticals Company Profile (NASDAQ:MACK)

About Merrimack Pharmaceuticals (MACK)

Merrimack Pharmaceuticals logoMerrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. Its therapeutic oncology candidates in clinical development include MM-398, MM-302, MM-121, MM-141 and MM-151. Its ONIVYDE (irinotecan liposome injection), also known as MM-398, is an encapsulation of the marketed chemotherapy drug irinotecan in a liposomal formulation. MM-302 is an antibody drug conjugated liposomal doxorubicin that targets the ErbB2 (HER2) receptor. MM-121 is a fully human monoclonal antibody that targets Erb-B2 Receptor Tyrosine Kinase 3 (ErbB3). MM-141 is a fully human tetravalent bispecific antibody designed to block tumor survival signals by targeting receptor complexes. MM-151 is an oligoclonal therapeutic designed to bind to non-overlapping epitopes of EGFR (ErbB1).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: MACK
  • CUSIP: 59032810
Key Metrics:
  • Previous Close: $3.04
  • 50 Day Moving Average: $3.13
  • 200 Day Moving Average: $4.46
  • 52-Week Range: $2.83 - $9.02
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.33
  • P/E Growth: -1.15
  • Market Cap: $396.93M
  • Outstanding Shares: 130,570,000
  • Beta: 1.92
  • Net Margins: -160.00%
  • Return on Assets: -96.01%
  • Debt-to-Equity Ratio: -0.96%
  • Current Ratio: 1.02%
  • Quick Ratio: 0.85%

Analyst Ratings

Consensus Ratings for Merrimack Pharmaceuticals (NASDAQ:MACK) (?)
Ratings Breakdown: 4 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $9.50 (212.50% upside)

Analysts' Ratings History for Merrimack Pharmaceuticals (NASDAQ:MACK)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
1/24/2017Cowen and CompanyReiterated RatingMarket PerformN/AView Rating Details
1/11/2017Robert W. BairdReiterated RatingNeutral$5.00N/AView Rating Details
11/10/2016JPMorgan Chase & Co.Reiterated RatingHold$7.00N/AView Rating Details
11/10/2016BTIG ResearchReiterated RatingNeutralN/AView Rating Details
8/5/2016Brean CapitalSet Price TargetBuy$16.00 -> $13.00N/AView Rating Details
5/20/2016MizuhoReiterated RatingBuy$13.00N/AView Rating Details
12/30/2015Oppenheimer Holdings Inc.Reiterated RatingBuyN/AView Rating Details
8/11/2015Cantor FitzgeraldReiterated RatingBuy$16.00N/AView Rating Details
5/13/2015GuggenheimInitiated CoverageBuy$15.00N/AView Rating Details
(Data available from 3/29/2015 forward)


Earnings History for Merrimack Pharmaceuticals (NASDAQ:MACK)
Earnings by Quarter for Merrimack Pharmaceuticals (NASDAQ:MACK)
Earnings History by Quarter for Merrimack Pharmaceuticals (NASDAQ:MACK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/1/2017Q416($0.21)($0.25)$50.44 million$61.20 millionViewListenView Earnings Details
11/9/2016Q316($0.27)($0.23)$41.00 million$28.07 millionViewListenView Earnings Details
8/4/2016Q216($0.33)($0.40)$33.35 million$33.70 millionViewN/AView Earnings Details
5/2/2016Q116($0.38)($0.33)$24.16 million$21.30 millionViewN/AView Earnings Details
2/25/2016Q415($0.41)($0.41)$31.73 million$21.42 millionViewListenView Earnings Details
11/9/2015Q315($0.40)($0.38)$14.04 million$16.44 millionViewN/AView Earnings Details
8/10/2015Q215($0.31)($0.21)$17.57 million$36.60 millionViewListenView Earnings Details
5/7/2015($0.30)($0.32)ViewN/AView Earnings Details
2/26/2015Q4($0.23)($0.09)ViewN/AView Earnings Details
11/10/2014($0.12)($0.27)ViewN/AView Earnings Details
8/11/2014($0.32)($0.17)ViewN/AView Earnings Details
5/1/2014Q114($0.30)($0.27)$11.93 million$13.03 millionViewN/AView Earnings Details
2/27/2014($0.29)($0.33)ViewN/AView Earnings Details
11/7/2013($0.34)($0.39)ViewN/AView Earnings Details
8/8/2013Q2 2013($0.28)($0.31)$13.68 million$18.45 millionViewN/AView Earnings Details
3/14/2013Q4 2012($0.26)($1.76)$11.77 million$12.58 millionViewN/AView Earnings Details
11/14/2012Q312($1.81)$8.60 million$11.30 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Merrimack Pharmaceuticals (NASDAQ:MACK)
Current Year EPS Consensus Estimate: $-0.47 EPS
Next Year EPS Consensus Estimate: $-0.57 EPS


Dividend History for Merrimack Pharmaceuticals (NASDAQ:MACK)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Merrimack Pharmaceuticals (NASDAQ:MACK)
Insider Ownership Percentage: 11.49%
Institutional Ownership Percentage: 73.14%
Insider Trades by Quarter for Merrimack Pharmaceuticals (NASDAQ:MACK)
Institutional Ownership by Quarter for Merrimack Pharmaceuticals (NASDAQ:MACK)
Insider Trades by Quarter for Merrimack Pharmaceuticals (NASDAQ:MACK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/25/2016Birgit M SchoeberlInsiderSell50,000$5.50$275,000.00View SEC Filing  
3/17/2016Michael E PorterDirectorBuy5,000$7.20$36,000.00View SEC Filing  
3/15/2016Michael E PorterDirectorBuy5,000$7.65$38,250.00View SEC Filing  
3/8/2016Michael E PorterDirectorBuy10,000$7.09$70,900.00View SEC Filing  
3/3/2016Michael E PorterDirectorBuy15,000$6.39$95,850.00View SEC Filing  
3/1/2016Michael E PorterDirectorBuy20,000$6.11$122,200.00View SEC Filing  
2/29/2016Vivian S LeeDirectorBuy35,000$5.50$192,500.00View SEC Filing  
2/29/2016William M McclementsInsiderBuy2,000$5.72$11,440.00View SEC Filing  
1/5/2016Edward J. StewartinsiderSell4,000$8.00$32,000.00View SEC Filing  
12/1/2015Edward J. StewartinsiderSell5,000$9.33$46,650.00View SEC Filing  
11/2/2015Edward J. StewartinsiderSell6,000$9.42$56,520.00View SEC Filing  
10/16/2015Edward J. StewartinsiderSell1,000$10.00$10,000.00View SEC Filing  
10/2/2015Edward J. StewartinsiderSell5,000$8.20$41,000.00View SEC Filing  
9/1/2015Edward J. StewartinsiderSell6,000$9.88$59,280.00View SEC Filing  
8/21/2015Michael E PorterDirectorBuy5,000$9.76$48,800.00View SEC Filing  
8/17/2015Edward J. StewartinsiderSell6,000$10.49$62,940.00View SEC Filing  
8/14/2015Michael E PorterDirectorBuy13,000$10.54$137,020.00View SEC Filing  
7/20/2015Ulrik B NielsenDirectorSell20,000$10.71$214,200.00View SEC Filing  
7/15/2015Edward J StewartInsiderSell6,000$11.84$71,040.00View SEC Filing  
7/15/2015William A SullivanCFOSell15,000$11.85$177,750.00View SEC Filing  
6/19/2015Ulrik B NielsenDirectorSell40,000$12.02$480,800.00View SEC Filing  
6/18/2015Edward J StewartInsiderSell2,000$12.00$24,000.00View SEC Filing  
6/15/2015Edward J StewartInsiderSell6,000$10.67$64,020.00View SEC Filing  
6/15/2015William A SullivanCFOSell15,000$10.65$159,750.00View SEC Filing  
5/19/2015Ulrik B NielsenDirectorSell40,000$13.04$521,600.00View SEC Filing  
5/13/2015Michael E PorterDirectorBuy8,284$11.79$97,668.36View SEC Filing  
4/20/2015Ulrik B NielsenDirectorSell40,000$12.88$515,200.00View SEC Filing  
4/15/2015Edward J StewartSVPSell8,000$12.79$102,320.00View SEC Filing  
4/15/2015William A SullivanCFOSell15,000$12.87$193,050.00View SEC Filing  
4/13/2015Gordon J FehrDirectorSell20,000$13.00$260,000.00View SEC Filing  
3/24/2015Robert J MulroyCEOSell114,368$11.71$1,339,249.28View SEC Filing  
3/23/2015Robert J MulroyCEOSell10,400$11.69$121,576.00View SEC Filing  
3/20/2015Michael E PorterDirectorBuy5,000$11.77$58,850.00View SEC Filing  
3/19/2015Ulrik B NielsenDirectorSell40,000$11.97$478,800.00View SEC Filing  
3/19/2015William A SullivanCFOSell15,000$11.97$179,550.00View SEC Filing  
3/17/2015Birgit M SchoeberlInsiderSell42,234$12.00$506,808.00View SEC Filing  
3/17/2015Edward J StewartSVPSell8,000$11.95$95,600.00View SEC Filing  
3/17/2015Michael E PorterDirectorBuy1,190$11.77$14,006.30View SEC Filing  
3/16/2015Birgit M SchoeberlInsiderSell20,897$12.00$250,764.00View SEC Filing  
3/16/2015Edward J StewartSVPSell6,000$11.93$71,580.00View SEC Filing  
3/11/2015Michael E PorterDirectorBuy5,000$11.33$56,650.00View SEC Filing  
3/2/2015Michael E PorterDirectorBuy5,000$10.93$54,650.00View SEC Filing  
2/23/2015Ulrik B NielsenDirectorSell20,000$10.91$218,200.00View SEC Filing  
2/20/2015Robert J MulroyCEOSell150,000$10.94$1,641,000.00View SEC Filing  
1/15/2015Edward J StewartSVPSell6,000$11.19$67,140.00View SEC Filing  
12/24/2014William A SullivanCFOSell15,000$10.70$160,500.00View SEC Filing  
12/23/2014Vivian S LeeDirectorBuy20,000$10.23$204,600.00View SEC Filing  
12/18/2014Anthony J SinskeyDirectorSell20,000$10.31$206,200.00View SEC Filing  
12/15/2014Edward J StewartSVPSell6,000$10.63$63,780.00View SEC Filing  
12/8/2014Robert J MulroyCEOSell200,000$9.84$1,968,000.00View SEC Filing  
12/2/2014Michael E PorterDirectorBuy8,000$8.71$69,680.00View SEC Filing  
11/21/2014Michael E PorterDirectorBuy11,909$8.87$105,632.83View SEC Filing  
11/18/2014Edward J StewartSVPSell5,000$8.55$42,750.00View SEC Filing  
11/14/2014Michael E PorterDirectorBuy5,000$8.29$41,450.00View SEC Filing  
11/13/2014Gary L CrockerDirectorBuy14,390$8.47$121,883.30View SEC Filing  
11/12/2014Michael E PorterDirectorBuy40,000$8.37$334,800.00View SEC Filing  
10/23/2014Edward J StewartSVPSell3,000$9.05$27,150.00View SEC Filing  
9/30/2014William A SullivanCFOSell105,282$8.61$906,478.02View SEC Filing  
9/29/2014William A SullivanCFOSell64,404$8.40$540,993.60View SEC Filing  
9/24/2014Edward J StewartSVPSell12,000$8.22$98,640.00View SEC Filing  
6/23/2014Gary L CrockerDirectorBuy36,000$6.84$246,240.00View SEC Filing  
5/20/2014Gary CrockerDirectorBuy4,000$6.69$26,760.00View SEC Filing  
5/19/2014Gary CrockerDirectorBuy9,400$6.68$62,792.00View SEC Filing  
5/16/2014Michael PorterDirectorBuy15,000$6.49$97,350.00View SEC Filing  
5/13/2014Anthony SinskeyDirectorBuy5,000$6.74$33,700.00View SEC Filing  
5/8/2014Michael PorterDirectorBuy10,000$6.59$65,900.00View SEC Filing  
5/7/2014Gary CrockerDirectorBuy4,400$6.77$29,788.00View SEC Filing  
5/6/2014Gary CrockerDirectorBuy17,500$6.89$120,575.00View SEC Filing  
5/5/2014Michael PorterDirectorBuy15,000$6.41$96,150.00View SEC Filing  
5/5/2014Robert MulroyCEOBuy5,000$6.31$31,550.00View SEC Filing  
12/17/2013Michael PorterDirectorBuy25,000$4.75$118,750.00View SEC Filing  
12/12/2013William McclementsSVPBuy4,000$4.26$17,040.00View SEC Filing  
12/10/2013Michael PorterDirectorBuy18,000$4.38$78,840.00View SEC Filing  
12/6/2013James QuigleyDirectorBuy39,000$4.70$183,300.00View SEC Filing  
12/4/2013Robert MulroyCEOBuy33,100$4.42$146,302.00View SEC Filing  
12/3/2013Sarah NashDirectorBuy47,500$4.17$198,075.00View SEC Filing  
12/2/2013William McclementsSVPBuy2,000$4.06$8,120.00View SEC Filing  
11/29/2013Anthony SinskeyDirectorBuy3,800$3.92$14,896.00View SEC Filing  
11/27/2013Gary CrockerDirectorBuy207,000$3.72$770,040.00View SEC Filing  
12/14/2012John MendelsohnDirectorBuy5,000$6.63$33,150.00View SEC Filing  
12/13/2012Gary L CrockerDirectorBuy36,500$6.77$247,105.00View SEC Filing  
12/10/2012Michael E PorterDirectorBuy10,000$6.08$60,800.00View SEC Filing  
9/14/2012Gary L CrockerDirectorBuy64,800$8.33$539,784.00View SEC Filing  
8/24/2012James H QuigleyDirectorBuy12,500$7.55$94,375.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Merrimack Pharmaceuticals (NASDAQ:MACK)
Latest Headlines for Merrimack Pharmaceuticals (NASDAQ:MACK)
DateHeadline logoMerrimack to Present at the 2017 American Association for Cancer Research Annual Meeting - March 27 at 10:32 AM logoMerrimack Pharmaceuticals Inc (MACK) Short Interest Down 8.7% in March - March 27 at 7:04 AM logoMerrimack Initiates Phase 1 Study of MM-310 in Solid Tumors - PR Newswire (press release) - March 25 at 9:22 AM logo​Merrimack asset sale prompts legal blowback - March 23 at 6:58 PM logoBRIEF-Merrimack Pharmaceuticals reports enrollment of 1st patient in phase 1 study of mm-310 - March 23 at 8:53 AM logoMerrimack Initiates Phase 1 Study of MM-310 in Solid Tumors - March 23 at 8:53 AM logoLawyer: former Merrimack employee accused of insider trading to fight charges - March 22 at 9:34 AM logoMerrimack Pharmaceuticals Inc (MACK) Sees Large Growth in Short Interest - March 10 at 11:04 AM logoMERRIMACK PHARMACEUTICALS INC Financials - March 7 at 6:12 PM logoMerrimack (MACK) Q4 Loss Lower than Expected, Revenues Top - March 2 at 6:38 PM logoEdited Transcript of MACK earnings conference call or presentation 1-Mar-17 1:30pm GMT - March 1 at 11:30 PM logoQ4 2016 Merrimack Pharmaceuticals Inc Earnings Release - Before Market Open - March 1 at 6:29 PM logo7:11 am Merrimack Pharma misses by $0.03, misses on revs - March 1 at 6:29 PM logoMerrimack reports 4Q loss - March 1 at 6:29 PM logoMerrimack Reports Fourth Quarter and Full-Year 2016 Financial Results - March 1 at 11:02 AM logoEarnings Reaction History: Merrimack Pharmaceuticals Inc, 36.4% Follow-Through Indicator, 7.9% Sensitive - March 1 at 11:02 AM logoMerrimack's (MACK) Q4 Loss In-Line With Estimates - March 1 at 11:02 AM logoMERRIMACK PHARMACEUTICALS INC Files SEC form 10-K, Annual Report - March 1 at 11:02 AM logoMerrimack Announces Timing of Fourth Quarter 2016 Investor Conference Call - February 22 at 6:32 PM logoFive things you need to know today, pitchers and catchers, Claude, and a cockroach - February 16 at 6:00 PM logoIs Merrimack Pharmaceuticals Worth Stashing in Portfolios? - Motley Fool - February 14 at 12:39 AM logoIs Merrimack Pharmaceuticals Worth Stashing in Portfolios? - Nasdaq - February 12 at 11:17 PM logo3 Stocks Begging for a Buyout - February 11 at 2:19 PM logoForm SC 13G/A MERRIMACK PHARMACEUTICAL Filed by: VANGUARD GROUP INC - February 10 at 7:13 PM logoCORRECTED-UPDATE 1-Merrimack Pharma employee arrested on U.S. insider trading charge - February 9 at 7:24 PM logoMERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Change in Directors - February 8 at 7:13 PM logoWhy Merrimack Pharmaceuticals Got Crushed 23.8% in January - Motley Fool - February 7 at 7:42 PM logoMerrimack Pharmaceuticals employee arrested, charged with insider trading - February 7 at 7:42 PM


Frequently Asked Questions for Merrimack Pharmaceuticals (NASDAQ:MACK)

What is Merrimack Pharmaceuticals' stock symbol?

Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK."

How were Merrimack Pharmaceuticals' earnings last quarter?

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) released its quarterly earnings results on Wednesday, March, 1st. The company reported ($0.25) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.21) by $0.04. The firm had revenue of $61.20 million for the quarter, compared to analysts' expectations of $50.44 million. The business's revenue for the quarter was up 186.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.41) earnings per share.

When will Merrimack Pharmaceuticals make its next earnings announcement?

Merrimack Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, May, 1st 2017.

Where is Merrimack Pharmaceuticals' stock going? Where will Merrimack Pharmaceuticals' stock price be in 2017?

6 brokers have issued 1 year target prices for Merrimack Pharmaceuticals' stock. Their forecasts range from $5.00 to $13.00. On average, they expect Merrimack Pharmaceuticals' stock price to reach $9.50 in the next twelve months.

What are analysts saying about Merrimack Pharmaceuticals stock?

Here are some recent quotes from research analysts about Merrimack Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Merrimack achieved a major boost with the FDA approval of Onivyde. Initial uptake of the drug has been encouraging and should boost the top line, going forward. Inclusion of the drug in the National Comprehensive Cancer Network (NCCN) pathway should also drive the drug’s sales. We are also positive on the company’s efforts to expand Onivyde’s label. Moreover, Merrimack’s collaboration with Shire for Onivyde is both financially and strategically beneficial. However, we are concerned by the company's sole dependence on Onivyde for growth. Also, Merrimack undertook a restructuring move to prioritize its R&D expenses on a focused set of oncology products and to strengthen its cash runway, which led to a 22% reduction in the headcount. Estimates have been mixed lately ahead of the company’s Q3 earnings release. The company has a mixed record of earnings surprises in the recent quarters." (10/19/2016)
  • 2. JPMorgan Chase & Co. analysts commented, "Our view that 2016 consensus estimates, while achievable, are perhaps not meaningfully beatable (and 2017 needs to moderate incrementally, in our view)."Key pipeline catalysts, while underappreciated, are weighted 2Q17+."Our expectation that R&D prioritization and search for a new CEO could take time (currently no timelines outlined)."A continued financing overhang (~12 months of cash)." (10/7/2016)

Are investors shorting Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals saw a decline in short interest in the month of March. As of March 15th, there was short interest totalling 24,549,211 shares, a decline of 8.7% from the February 28th total of 26,888,026 shares. Based on an average trading volume of 1,924,732 shares, the short-interest ratio is currently 12.8 days. Approximately 19.9% of the company's stock are sold short.

Who owns Merrimack Pharmaceuticals stock?

Merrimack Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), State Street Corp (4.13%), Franklin Resources Inc. (3.06%), Teachers Advisors LLC (1.93%), Indus Capital Partners LLC (0.81%) and Norges Bank (0.72%). Company insiders that own Merrimack Pharmaceuticals stock include Birgit M Schoeberl, Edward J Stewart, Gordon J Fehr, Michael E Porter, Ulrik B Nielsen, Vivian S Lee, William A Sullivan and William M Mcclements.

Who sold Merrimack Pharmaceuticals stock? Who is selling Merrimack Pharmaceuticals stock?

Merrimack Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Teachers Advisors LLC, First Republic Investment Management Inc., UBS Asset Management Americas Inc., Private Advisor Group LLC, Princeton Portfolio Strategies Group LLC and Metropolitan Life Insurance Co. NY.

Who bought Merrimack Pharmaceuticals stock? Who is buying Merrimack Pharmaceuticals stock?

Merrimack Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Norges Bank, State Street Corp, Indus Capital Partners LLC, Guggenheim Capital LLC, ING Groep NV, FMR LLC and Perceptive Advisors LLC. Company insiders that have bought Merrimack Pharmaceuticals stock in the last two years include Michael E Porter, Vivian S Lee and William M Mcclements.

How do I buy Merrimack Pharmaceuticals stock?

Shares of Merrimack Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Merrimack Pharmaceuticals stock cost?

One share of Merrimack Pharmaceuticals stock can currently be purchased for approximately $3.04.

Merrimack Pharmaceuticals (MACK) Chart for Wednesday, March, 29, 2017

This page was last updated on 3/29/2017 by Staff